Immunotherapy in Melanoma | Specialty

Dr. Luke on the FDA Approval of Adjuvant Nivolumab in Melanoma

December 21st 2017

Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the FDA approval of nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.

FDA Approves Adjuvant Nivolumab for Melanoma

December 21st 2017

The FDA has approved nivolumab as an adjuvant treatment for patients with completely resected melanoma with lymph node involvement or metastatic disease.

Dr. Schadendorf Discusses Sequencing Agents in Melanoma

December 21st 2017

Dirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses sequencing agents in melanoma.

Dr. Kim Discusses PD-L1 as a Biomarker in Lung Cancer

December 21st 2017

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses PD-L1 as a biomarker in lung cancer.

Immunotherapy Resistance Remains a Puzzle

December 15th 2017

Checkpoint blockade immunotherapy has been hailed as a significant advance in anticancer treatment. Yet only a subset of patients experience long-term cancer remission as a result of these therapies, because a significant number of those who initially respond eventually develop resistance.

Dr. Landi on the Association Between Genetic Variance and Melanoma Risk

December 14th 2017

Maria Teresa Landi, MD, PhD, senior investigator, Integrative Tumor Epidemiology Branch, National Cancer Institute, discusses the association between genetic variance and melanoma risk.

Positive Topline Results Announced for Cemiplimab in Advanced CSCC

December 14th 2017

Results from EMPOWER-CSCC 1 showed that cemiplimab (REGN2810) induced an overall response rate of 46.3% in patients with advanced cutaneous squamous cell carcinoma.

Standard Adjuvant Therapy for Melanoma Within Reach

December 12th 2017

Michael B. Atkins, MD, discusses hotly debated adjuvant treatment options for patients with melanoma, and the potential for neoadjuvant therapy.

Combination Therapies Push Melanoma Field Forward

December 12th 2017

Michael A. Postow, MD, discusses the evolution of combination therapies for patients with melanoma.

Expert Says Melanoma Clinical Trials Should Include More Patients With Brain Mets

December 12th 2017

Harriet Kluger, MD, discussed the lack of clinical trial inclusion for patients with melanoma who have brain metastases, as well as promising regimens coming down the pike.

Dr. Sznol Discusses the Role of Surgery in Melanoma

December 8th 2017

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the role of surgery in the treatment of patients with melanoma.

Dr. Atkins Discusses the Adjuvant Treatment of Melanoma

December 8th 2017

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the adjuvant treatment of melanoma.

Dr. Postow Discusses Combination Therapy for Melanoma

December 6th 2017

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combination therapy for patients with melanoma.

Ipilimumab Effective in Adolescents With Advanced Melanoma

November 30th 2017

Ipilimumab was associated with a 1-year overall survival rate of 75% in adolescent patients with stage III/IV unresectable malignant melanoma.

Dr. Atkinson on Novel Combinations in Melanoma

November 30th 2017

Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses novel combinations for the treatment of patients with melanoma.

Dr. Luke on the Clinical Trial Landscape for Melanoma

November 29th 2017

Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the clinical trial landscape for melanoma

Dr. Soyer Discusses the Role of Technology in Melanoma

November 21st 2017

Peter Soyer, MD, academic dermatologist, professor, The University of Queensland Diamantina Institute, discusses the role of technology in melanoma.

The Future Role of PARP Inhibition in Ovarian Cancer

November 20th 2017

Combinations With PARP Inhibitors for Ovarian Cancer

November 20th 2017

Ovarian Cancer: Selecting an Appropriate PARP Inhibitor

November 20th 2017